Durham-based BioCryst Pharmaceuticals has received an additional $5.5 million in federal funding to further develop BCX4430, its experimental drug for treating Ebola and other viral infections.
With the latest funding from the National Institute of Allergy and Infectious Diseases, announced Tuesday, BioCryst’s total federal funding could go as high as $39.5 million if all contract options are exercised.
“The additional support from NIAID emphasizes the importance of advancing the development of treatment options for deadly emerging infectious diseases such as Ebola virus and Marburg virus,” William P. Sheridan, the company’s chief medical officer, said in a prepared statement.
In March, BioCryst reported that BCX4430 successfully treated mice infected with the Zika virus. The drug also has had success in treating monkeys infected with Ebola and Marburg viruses and is now being tested in humans.
The new funding is for additional animal tests and for further assessment of safe and effective doses for humans.